Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.
HB2584 • 2026
INS-PRIOR AUTH HIV DRUG ACCESS
This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.
Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.
INS-PRIOR AUTH HIV DRUG ACCESS
These notes stay tied to the official amendment files and metadata from the legislature.
Plain English: Illinois General Assembly - Full Text of HB2584 Select Language × The Illinois General Assembly offers the Google Translate™ service for visitor convenience.
Plain English: Illinois General Assembly - Full Text of HB2584 Select Language × The Illinois General Assembly offers the Google Translate™ service for visitor convenience.
Rule 3-9(a) / Re-referred to Assignments
Senate Committee Amendment No. 1 Rule 3-9(a) / Re-referred to Assignments
Senate Committee Amendment No. 2 Rule 3-9(a) / Re-referred to Assignments
Rule 2-10 Committee/3rd Reading Deadline Established As May 31, 2026
Rule 2-10 Committee Deadline Established As May 22, 2026
Added as Alternate Co-Sponsor Sen. Rachel Ventura
Rule 2-10 Committee Deadline Established As May 15, 2026
Senate Committee Amendment No. 2 Assignments Refers to Insurance
Senate Committee Amendment No. 2 Filed with Secretary by Sen. Sara Feigenholtz
Senate Committee Amendment No. 2 Referred to Assignments
Added as Alternate Co-Sponsor Sen. Mark L. Walker
Senate Committee Amendment No. 1 Assignments Refers to Insurance
Senate Committee Amendment No. 1 Filed with Secretary by Sen. Sara Feigenholtz
Senate Committee Amendment No. 1 Referred to Assignments
Re-assigned to Insurance
Added Chief Co-Sponsor Rep. Stephanie A. Kifowit
Removed Co-Sponsor Rep. Stephanie A. Kifowit
Added as Alternate Co-Sponsor Sen. David Koehler
Alternate Chief Sponsor Changed to Sen. Sara Feigenholtz
Added as Alternate Chief Co-Sponsor Sen. Laura Fine
Added as Alternate Co-Sponsor Sen. Javier L. Cervantes
Added as Alternate Co-Sponsor Sen. Mary Edly-Allen
Added as Alternate Co-Sponsor Sen. Laura M. Murphy
Added as Alternate Co-Sponsor Sen. Celina Villanueva
Rule 3-9(a) / Re-referred to Assignments
Rule 2-10 Committee Deadline Established As June 1, 2025
Re-referred to Insurance
Rule 3-9(a) / Re-referred to Assignments
Rule 2-10 Committee Deadline Established As May 23, 2025
Added as Alternate Chief Co-Sponsor Sen. Graciela Guzmán
Added as Alternate Co-Sponsor Sen. Mike Simmons
Added as Alternate Co-Sponsor Sen. Karina Villa
Added as Alternate Chief Co-Sponsor Sen. Sara Feigenholtz
Assigned to Appropriations- Health and Human Services
Arrive in Senate
Placed on Calendar Order of First Reading
Chief Senate Sponsor Sen. Laura Fine
First Reading
Referred to Assignments
House Floor Amendment No. 2 Adopted
Placed on Calendar Order of 3rd Reading - Short Debate
Third Reading - Short Debate - Passed 078-035-000
Added Co-Sponsor Rep. Nicolle Grasse
Added Chief Co-Sponsor Rep. Harry Benton
Added Co-Sponsor Rep. Anna Moeller
House Floor Amendment No. 2 Rules Refers to Insurance Committee
House Floor Amendment No. 2 Recommends Be Adopted Insurance Committee ; 010-004-000
House Floor Amendment No. 2 Filed with Clerk by Rep. Kelly M. Cassidy
House Floor Amendment No. 2 Referred to Rules Committee
Added Co-Sponsor Rep. Janet Yang Rohr
Fiscal Note Filed
Racial Impact Note Filed
Added Co-Sponsor Rep. Hoan Huynh
Added Co-Sponsor Rep. Ann M. Williams
Second Reading - Short Debate
Held on Calendar Order of Second Reading - Short Debate
Added Co-Sponsor Rep. Martha Deuter
Added Co-Sponsor Rep. Lindsey LaPointe
Added Chief Co-Sponsor Rep. Terra Costa Howard
Chief Co-Sponsor Changed to Rep. Terra Costa Howard
Judicial Note Filed
Balanced Budget Note Filed
Placed on Calendar 2nd Reading - Short Debate
Housing Affordability Impact Note Filed
Pension Note Filed
State Debt Impact Note Filed
House Committee Amendment No. 1 Rules Refers to Insurance Committee
Balanced Budget Note Requested by Rep. Kelly M. Cassidy
Correctional Note Requested by Rep. Kelly M. Cassidy
Fiscal Note Requested by Rep. Kelly M. Cassidy
Home Rule Note Requested by Rep. Kelly M. Cassidy
Housing Affordability Impact Note Requested by Rep. Kelly M. Cassidy
Judicial Note Requested by Rep. Kelly M. Cassidy
Land Conveyance Appraisal Note Requested by Rep. Kelly M. Cassidy
Pension Note Requested by Rep. Kelly M. Cassidy
Racial Impact Note Requested by Rep. Kelly M. Cassidy
State Debt Impact Note Requested by Rep. Kelly M. Cassidy
State Mandates Fiscal Note Requested by Rep. Kelly M. Cassidy
House Committee Amendment No. 1 Adopted in Insurance Committee ; by Voice Vote
Do Pass as Amended / Short Debate Insurance Committee ; 013-003-000
House Committee Amendment No. 1 Filed with Clerk by Rep. Kelly M. Cassidy
House Committee Amendment No. 1 Referred to Rules Committee
Added Co-Sponsor Rep. Camille Y. Lilly
Added Co-Sponsor Rep. Diane Blair-Sherlock
Added Co-Sponsor Rep. Stephanie A. Kifowit
Added Co-Sponsor Rep. Jennifer Gong-Gershowitz
Added Co-Sponsor Rep. Daniel Didech
Added Co-Sponsor Rep. Bob Morgan
Added Co-Sponsor Rep. Jehan Gordon-Booth
Added Co-Sponsor Rep. Justin Slaughter
Added Co-Sponsor Rep. Lilian Jiménez
Added Co-Sponsor Rep. Rita Mayfield
Added Co-Sponsor Rep. Edgar González, Jr.
Added Co-Sponsor Rep. Tracy Katz Muhl
Added Co-Sponsor Rep. Kevin John Olickal
Added Co-Sponsor Rep. Will Guzzardi
Added Co-Sponsor Rep. Mary Beth Canty
Added Co-Sponsor Rep. Laura Faver Dias
Added Co-Sponsor Rep. Norma Hernandez
Added Co-Sponsor Rep. Abdelnasser Rashid
Added Co-Sponsor Rep. Nabeela Syed
Added Co-Sponsor Rep. Barbara Hernandez
Added Co-Sponsor Rep. Lisa Davis
Added Co-Sponsor Rep. Amy Briel
Added Co-Sponsor Rep. Michael Crawford
Assigned to Insurance Committee
First Reading
Referred to Rules Committee
Filed with the Clerk by Rep. Kelly M. Cassidy
INS-PRIOR AUTH HIV DRUG ACCESS
Illinois General Assembly - Full Text of HB2584 Select Language × The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein. Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet. The English language version is always the official and authoritative version of this website. NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window. Choose Language English Afrikaans Albanian Arabic Armenian Azerbaijani Basque Bengali Bosnian Catalan Croatian Czech Danish Dutch Esperanto Estonian Filipino Finnish French Galician Georgian German Greek Gujarati Haitian Creole Hausa Hawaiian Hebrew Hindi Hungarian Icelandic Indonesian Interlingua Interlingue Inuktitut Irish Italian Japanese Javanese Kannada Khmer Korean Latin Latvian Lithuanian Luxembourgish Macedonian Malagasy Malayalam Maltese Maori Marathi Myanmar Nepali Norwegian Odia Pashto Punjabi Romanian Russian Samoan Sango Sanskrit Sardinian Sindhi Sinhala Slovak Slovenian Somali Southern Sotho Spanish Sundanese Swahili Swedish Tamil Telugu Thai Tigrinya Tonga Turkish Ukrainian Urdu Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Powered by Translate Close Illinois General Assembly Top Navigation Bar Translate Learn Select General Assembly Search the 104th General Assembly Enter search terms for legislation, members, committees, or schedules. ILGA.GOV LEGISLATION & LAWS Bills & Resolutions Public Acts Illinois Compiled Statutes Illinois Constitution Search Legislation Glossary Guide Reports & Inquiry Legislative Reports Special Reports FTP Site Legislator Lookup Capitol Complex Phone Numbers Rules & Regulations Illinois Register Administrative Rules Senate Members Schedules Committees Request for Remote Testimony Journals Transcripts Rules Audio/Video FOIA Information Senate Employment Opportunities Media Guidelines House Members Schedules Committees Submit testimony for House Committees Journals Transcripts Rules Audio/Video FOIA Information House Employment Opportunities Log In Mobile Top Bar Search the 104th General Assembly Enter keywords to search the Illinois General Assembly website. Full Text of HB2584 Home Legislation Full Text HB2584 - 104th General Assembly Bill Status Full Text Votes Witness Slips Select Menu Bill Status Full Text Votes Witness Slips Printer Friendly Version Introduced Engrossed House Amendment 001 House Amendment 002 Senate Amendment 001 Senate Amendment 002 Printer Friendly Version Introduced Engrossed House Amendment 001 House Amendment 002 Senate Amendment 001 Senate Amendment 002 Open PDF HB2584 Engrossed LRB104 08321 BAB 18372 b 1 AN ACT concerning regulation. 2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly: 4 Section 5. The Illinois Insurance Code is amended by 5 changing Section 356z.60 as follows: 6 (215 ILCS 5/356z.60) 7 Sec. 356z.60. Coverage for abortifacients, hormonal 8 therapy, and human immunodeficiency virus pre-exposure 9 prophylaxis and post-exposure prophylaxis. 10 (a) As used in this Section: 11 "Abortifacients" means any medication administered to 12 terminate a pregnancy as prescribed or ordered by a health 13 care professional. 14 "Health care professional" means a physician licensed to 15 practice medicine in all of its branches, licensed advanced 16 practice registered nurse, or physician assistant. 17 "Hormonal therapy medication" means hormonal treatment 18 administered to treat gender dysphoria. 19 "Therapeutic equivalent version" means drugs, devices, or 20 products that can be expected to have the same clinical effect 21 and safety profile when administered to patients under the 22 conditions specified in the labeling and that satisfy the 23 following general criteria: HB2584 Engrossed - 2 - LRB104 08321 BAB 18372 b 1 (1) it is approved as safe and effective; 2 (2) it is a pharmaceutical equivalent in that it: 3 (A) contains identical amounts of the same active 4 drug ingredient in the same dosage form and route of 5 administration; and 6 (B) meets compendial or other applicable standards 7 of strength, quality, purity, and identity; 8 (3) it is bioequivalent in that: 9 (A) it does not present a known or potential 10 bioequivalence problem and it meets an acceptable in 11 vitro standard; or 12 (B) if it does present such a known or potential 13 problem, it is shown to meet an appropriate 14 bioequivalence standard; 15 (4) it is adequately labeled; and 16 (5) it is manufactured in compliance with Current Good 17 Manufacturing Practice regulations adopted by the United 18 States Food and Drug Administration. 19 (b) An individual or group policy of accident and health 20 insurance amended, delivered, issued, or renewed in this State 21 on or after January 1, 2024 shall provide coverage for all 22 abortifacients, hormonal therapy medication, human 23 immunodeficiency virus pre-exposure prophylaxis, and 24 post-exposure prophylaxis drugs approved by the United States 25 Food and Drug Administration, and follow-up services related 26 to that coverage, including, but not limited to, management of HB2584 Engrossed - 3 - LRB104 08321 BAB 18372 b 1 side effects, medication self-management or adherence 2 counseling, risk reduction strategies, and mental health 3 counseling. This coverage shall include drugs approved by the 4 United States Food and Drug Administration that are prescribed 5 or ordered for off-label use for the purposes described in 6 this Section. On or after the effective date of this 7 amendatory Act of the 104th General Assembly, this coverage 8 shall include pre-PrEP HIV screening, sexually transmitted 9 infection screening, kidney function analysis, routine 10 laboratory testing, and routine provider visits. 11 (c) The coverage required under subsection (b) is subject 12 to the following conditions: 13 (1) If the United States Food and Drug Administration 14 has approved one or more therapeutic equivalent versions 15 of an abortifacient drug, a policy is not required to 16 include all such therapeutic equivalent versions in its 17 formulary so long as at least one is included and covered 18 without cost sharing and in accordance with this Section. 19 (2) If an individual's attending provider recommends a 20 particular drug approved by the United States Food and 21 Drug Administration based on a determination of medical 22 necessity with respect to that individual, the plan or 23 issuer must defer to the determination of the attending 24 provider and must cover that service or item without cost 25 sharing. 26 (3) If a drug is not covered, plans and issuers must HB2584 Engrossed - 4 - LRB104 08321 BAB 18372 b 1 have an easily accessible, transparent, and sufficiently 2 expedient process that is not unduly burdensome on the 3 individual or a provider or other individual acting as a 4 patient's authorized representative to ensure coverage 5 without cost sharing. 6 The conditions listed under this subsection (c) also apply 7 to drugs prescribed for off-label use as abortifacients. 8 (d) Except as otherwise provided in this Section, a policy 9 subject to this Section shall not impose a deductible, 10 coinsurance, copayment, or any other cost-sharing requirement 11 on the coverage provided. The provisions of this subsection do 12 not apply to coverage of procedures to the extent such 13 coverage would disqualify a high-deductible health plan from 14 eligibility for a health savings account pursuant to the 15 federal Internal Revenue Code, 26 U.S.C. 223. 16 (e) Except as otherwise authorized under this Section, a 17 policy shall not impose any restrictions or delays on the 18 coverage required under this Section. 19 (f) The coverage requirements in this Section for 20 abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 21 apply to a multistate plan that does not provide coverage for 22 abortion. 23 (g) If the Department concludes that enforcement of any 24 coverage requirement of this Section for abortifacients may 25 adversely affect the allocation of federal funds to this 26 State, the Department may grant an exemption to that HB2584 Engrossed - 5 - LRB104 08321 BAB 18372 b 1 requirement, but only to the minimum extent necessary to 2 ensure the continued receipt of federal funds. 3 (Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 4 Section 10. The Prior Authorization Reform Act is amended 5 by adding Section 52 as follows: 6 (215 ILCS 200/52 new) 7 Sec. 52. Prior authorization for certain prescription 8 drugs; prohibited. A health insurance issuer may not require 9 prior authorization for the following prescription drug types 10 and their therapeutic equivalents approved by the United 11 States Food and Drug Administration: human immunodeficiency 12 virus pre-exposure prophylaxis and post-exposure prophylaxis 13 medication or human immunodeficiency virus treatment 14 medication. 15 Section 99. Effective date. This Act takes effect January 16 1, 2027. Footer Disclaimer This site is maintained for the Illinois General Assembly by the Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706. Contact ILGA Webmaster ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies. Read About Cookies ILGA.GOV 2026 ILGA.gov | All Rights Reserved | ADA | Disclaimers | Learn This site is maintained for the Illinois General Assembly by the Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706. Contact ILGA Webmaster ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies. Read About Cookies ILGA.GOV 2026 ILGA.gov | All Rights Reserved | ADA | Disclaimers | Learn